AGRX:NSD-Agile Therapeutics, Inc (USD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSD

Last Closing Price

USD 1.86

Change

-0.29 (-13.49)%

Market Cap

USD 0.19B

Volume

2.21M

Average Target Price

USD 7.00 (+276.34%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Agile Therapeutics, Inc., a women's healthcare company, focuses on the research, development, and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other transdermal contraceptive products, including AG200-ER, a regimen that allows a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide shorter and lighter periods; AG200-ER (SmP), a regimen to allow a woman to extend the length of her cycle, as well as experience shorter and lighter periods; and AG890, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was founded in 1997 and is headquartered in Princeton, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-31 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MYL Mylan N.V

-0.16 (-1.06%)

USD7.68B 496.00 5.94
MNTA Momenta Pharmaceuticals, Inc

-1.54 (-5.36%)

USD3.13B N/A -8.63
CRON Cronos Group Inc

-0.67 (-10.57%)

USD2.14B 11.60 N/A
IRWD Ironwood Pharmaceuticals, Inc

-0.24 (-2.32%)

USD1.60B 73.12 14.63
PCRX Pacira BioSciences, Inc

-0.18 (-0.53%)

USD1.36B 961.92 26.99
TCDA Tricida, Inc

-1.35 (-5.78%)

USD1.20B N/A -5.02
SUPN Supernus Pharmaceuticals, Inc

+0.83 (+4.84%)

USD0.90B 8.17 5.64
TLRY Tilray, Inc

+0.27 (+4.08%)

USD0.82B N/A -4.50
PAHC Phibro Animal Health Corporati..

+1.53 (+6.76%)

USD0.82B 21.55 11.30
AMPH Amphastar Pharmaceuticals, Inc

-0.28 (-1.85%)

USD0.70B 15.43 37.49

ETFs Containing AGRX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -25.60% 59% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.60% 59% F 52% F
Trailing 12 Months  
Capital Gain 25.68% 89% B+ 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.68% 89% B+ 90% A-
Trailing 5 Years  
Capital Gain -80.21% 41% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -80.21% 41% F 16% F
Average Annual (5 Year Horizon)  
Capital Gain 7.91% 55% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.91% 55% F 26% F
Risk Return Profile  
Volatility (Standard Deviation) 112.19% 5% F 8% F
Risk Adjusted Return 7.05% 58% F 31% F
Market Capitalization 0.19B 58% F 49% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.28 45% F 27% F
Price / Cash Flow Ratio -11.93 89% B+ 87% B+
EV/EBITDA -5.82 77% C+ 83% B
Management Effectiveness  
Return on Equity -56.45% 53% F 21% F
Return on Invested Capital -57.22% 36% F 17% F
Return on Assets -32.77% 25% F 13% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.50 84% B 84% B
Short Percent 10.33% 43% F 26% F
Beta 1.06 58% F 46% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.